Evidence of Differential Selection of HIV-1 Variants Carrying Drug-Resistant Mutations in Seroconverters

Objectives To estimate the relative efficiency of transmission of different HIV-1 drug-resistance mutations from patients failing treatment, considered as potential transmitters (PTs), to seroconverters (SCs). Design Ecological cross-sectional study. Methods HIV-1 protease and reverse transcriptase (RT) sequence data, obtained from 155 SCs and 2,690 PTs at the Department of Molecular Biology of the University of Siena, Italy, in the period 1997–2004 were used. The efficiency of transmission was studied by odds ratio (OR) analysis and evaluation of 95% confidence intervals (95% CIs). For mutations not detected in viruses from SCs, a binomial probability model was used, assuming P-values <0.05 as indicative of a negative selection at transmission. Results The overall prevalence of drug mutations associated with nucleoside reverse transcriptase inhibitors (NRTIs), non-NRTIs (NNRTIs) and protease inhibitors (PIs) was 13.2%, 4.6% and 2.0% in SCs, and 69.9%, 27.6% and 33.7% in PTs, respectively. Among RT mutations present both in PTs and SCs, M184I/V and T215F/Y had the lowest relative efficiency of transmission, whereas V118I, Y181C/I and K219E/Q showed the highest relative efficiency. Of the three major protease mutations that could be evaluated by this approach, M46I/L had a lower rate of transmission than I84V and L90M. Among the mutations not detected in viruses from SCs, the RT E44D, V108I, Q151M and Y188C/H/L, and the protease D30N, G48V and V82A/F/S/T substitutions appeared to be negatively selected. Conclusions The transmission rate of drug-resistant HIV-1 variants may be differentially affected by the mutational pattern. The binomial model enabled to evaluate the negative selection against specific substitutions. Given the low prevalence of some resistance mutations in SCs, very large data sets are required to evaluate the potential selection of such mutations.

[1]  Amalio Telenti,et al.  Update of the Drug Resistance Mutations in HIV-1: 2005. , 2005, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[2]  M. Wainberg,et al.  Diminished Representation of HIV-1 Variants Containing Select Drug Resistance-Conferring Mutations in Primary HIV-1 Infection , 2004, Journal of acquired immune deficiency syndromes.

[3]  V. Soriano,et al.  Evidence for differences in the sexual transmission efficiency of HIV strains with distinct drug resistance genotypes. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  Terri Wrin,et al.  The prevalence of antiretroviral drug resistance in the United States , 2004, AIDS.

[5]  A. Monforte,et al.  Prevalence of HIV-1 primary drug resistance in seroconverters of the ICoNA cohort over the period 1996-2001. , 2004, Journal of acquired immune deficiency syndromes.

[6]  D. Pillay,et al.  Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000. , 2004, The Journal of antimicrobial chemotherapy.

[7]  Alessandro Cozzi-Lepri,et al.  Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy , 2004, AIDS.

[8]  P. Pezzotti,et al.  Epidemiological changes in AIDS and HIV infection in Italy , 2003, Scandinavian journal of infectious diseases. Supplementum.

[9]  J. Fantini,et al.  Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997–2002) based on an analysis of over 7000 genotypes , 2003, AIDS.

[10]  A. Telenti,et al.  Infrequent Transmission of HIV-1 Drug-Resistant Variants , 2003, Antiviral therapy.

[11]  Elizabeth Connick,et al.  Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.

[12]  J. Kahn,et al.  Time trends in primary HIV-1 drug resistance among recently infected persons. , 2002, JAMA.

[13]  M. Zazzi,et al.  Performance of an in-house genotypic antiretroviral resistance assay in patients pretreated with multiple human immunodeficiency virus type 1 protease and reverse transcriptase inhibitors. , 2002, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[14]  W. Heneine,et al.  Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  H. Gershengorn,et al.  Predicting the unpredictable: Transmission of drug-resistant HIV , 2001, Nature Medicine.

[16]  D. Pillay,et al.  Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom , 2001, BMJ : British Medical Journal.

[17]  T. Quinn,et al.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.

[18]  JD Lundgren,et al.  Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.

[19]  Myron S. Cohen,et al.  Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis , 1998, The Lancet.

[20]  F. Brun-Vézinet,et al.  Switch to Unusual Amino Acids at Codon 215 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene in Seroconvertors Infected with Zidovudine-Resistant Variants , 1998, Journal of Virology.

[21]  A. Iversen,et al.  HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. Copenhagen AIDS Cohort Study Group. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.